A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms SOURCE
- Sponsors AstraZeneca
- 13 Mar 2018 Planned End Date changed from 26 Nov 2020 to 15 Dec 2020.
- 13 Mar 2018 Planned primary completion date changed from 26 Nov 2020 to 15 Dec 2020.
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.